Senseonics Holdings, Inc. (SENS)
Summary
Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership
SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Senseonics Holdings, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 144 | $959.04 | $738.07 | -$220.97 | -23.04% |
| RS Richard Slavik Newbridge Financial Services Group Inc. | 920 | $5,078.4 | $4,733.4 | -$345 | -6.79% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 15,300 | $101,898 | $78,718.5 | -$23,179.5 | -22.75% |
| SP Samantha Pierangeli City State Bank | 138 | $761.76 | $703.8 | -$57.96 | -7.61% |
 Amanda Hawley Atria Wealth Solutions Inc. | 560 | $12,964 | $2,884 | -$10,080 | -77.75% |
Senseonics Holdings, Inc. (SENS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Senseonics Holdings, Inc. ever had a stock split?
Senseonics Holdings, Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Timothy T. Goodnow CEO | AMEX Exchange | 81727U303 CUSIP |
| US Country | 130 Employees | - Last Dividend | 20 Oct 2025 Last Split | 17 Mar 2016 IPO Date |
Overview
Senseonics Holdings, Inc. is a medical technology entity dedicated to advancing diabetes care through its innovative continuous glucose monitoring (CGM) solutions. Founded in 1996, with its headquarters set in Germantown, Maryland, Senseonics has been at the forefront of offering advanced CGM systems, tailored for individuals living with diabetes across the United States, Europe, the Middle East, and Africa. The company's primary commitment is to enhance the quality of diabetes management for its users, allowing for real-time and accurate glucose level monitoring, fundamentally changing how people with diabetes manage their condition. Senseonics not only develops and commercializes these CGM systems but also ensures their accessibility to healthcare providers and patients via a robust network of distributors and strategic fulfillment partners. Additionally, the company values collaborative efforts for innovation, as manifested in its partnership with the University Hospitals Accountable Care Organization, aiming to elevate care delivery and outcomes for those managing diabetes.
Products and Services
Eversense
As the initial offering in Senseonics' product line, the Eversense CGM system represents a breakthrough in diabetes management technology. This system is renowned for incorporating an under-the-skin sensor that continuously tracks glucose levels, thus providing real-time, accurate readings. Paired with a removable and rechargeable smart transmitter, Eversense amplifies the convenience and efficiency of monitoring glucose levels, offering a seamless diabetes management experience.
Eversense XL
Building upon the foundation laid by the original Eversense system, the Eversense XL extends the capabilities of continuous glucose monitoring with an enhanced duration of its under-the-skin sensor. Designed for long-term diabetes management, the Eversense XL aims to provide an even more convenient and less intrusive experience for users, reducing the frequency of sensor replacements and thereby improving the overall quality of life for individuals managing their glucose levels.
Eversense E3
The latest innovation in Senseonics' portfolio, the Eversense E3 CGM system, propels glucose monitoring to new heights with a sensor capable of providing accurate glucose measurements for up to six months. This extended duration underscores Senseonics' commitment to advancing diabetes care by minimizing the intrusion and maintenance associated with diabetes management. The Eversense E3 system combines the enduring accuracy of its sensor technology with a user-friendly app and a smart transmitter, ensuring that users have access to real-time glucose data at their fingertips, empowering them to make informed decisions about their diabetes management.
